Thursday, February 9, 2023
THE SENIOR HEALTH LETTER
No Result
View All Result
  • Home
  • Home Care
  • Elder Care
  • Wellness
  • Dementia
  • Caregivers
  • Alzheimer’s
  • Assisted living
  • Mindfulness
  • Seniors advocate
The Senior Health Letter
No Result
View All Result
Home Alzheimer's

nQ Medical, a Digital Biomarker Discovery Platform, Unveils Latest Alzheimer’s Disease Clinical Trial Results at AD/PD 2021 International Conference | News

Delmar by Delmar
March 11, 2021
in Alzheimer's
0
nQ Medical, a Digital Biomarker Discovery Platform, Unveils Latest Alzheimer’s Disease Clinical Trial Results at AD/PD 2021 International Conference | News
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter


CAMBRIDGE, Mass., March 11, 2021 /PRNewswire-PRWeb/ — nQ Medical is proud to be a Gold Sponsor of the AD/PD 2021, the fifteenth Worldwide Convention on Alzheimer’s and Parkinson’s Ailments and associated neurological issues, held this week. Throughout the three occasions at AD/PD, nQ will probably be revealing the most recent knowledge from its “Validation of passive typing monitoring as an indicator of cognitive impairment within the AD spectrum” research, carried out on the Cleveland Clinic Lou Ruvo Heart for Mind Well being, Las Vegas.

Alzheimer’s illness is a neurodegenerative dysfunction that begins with delicate cognitive signs (sometimes short-term reminiscence loss) invariably progressing over the course of years to many years to dementia, useful impairment, and dying. Affecting greater than 5 million folks in the USA, it’s the commonest neurodegenerative illness. Advancing age is the strongest danger issue for growing the illness. Because of this each dwelling particular person over the age of 65 is in danger.

The financial and societal burden that Alzheimer’s illness imposes represents an rising public well being disaster for the USA, and extra broadly, the growing world (the place the vast majority of new circumstances are anticipated to happen). There may be an pressing have to determine people manifesting the preliminary signs of the illness. Identification of those people will permit for testing of recent brokers in medical trials, allow modification of life-style elements that will impression illness course, and, maybe, most significantly, symbolize an important time level to provoke remedy for Alzheimer’s illness (if and when new drugs are found).

Though a number of diagnostic assessments can be found that may determine sufferers within the earliest phases of the illness, these assessments are prohibitively costly (amyloid PET) or invasive (spinal faucet) and usually are not possible for screening tens of millions of at-risk people. New screening instruments which can be cheap, scalable, and minimally invasive are urgently wanted to be able to fight the looming Alzheimer’s illness epidemic.

A long time of analysis has confirmed that delicate errors on cognitive duties can predict those that will progress from gentle signs to Alzheimer’s dementia. Right now, these assessments are costly to investigate, time-consuming, and never extensively out there. Moreover, knowledge is often collected at discrete time factors at a testing heart, making it vulnerable to the influences of extraneous elements (i.e. a poor night time’s sleep, nervousness, a “unhealthy day”, and many others.). The power to pattern cognitive efficiency constantly and within the particular person’s pure surroundings would symbolize a serious achievement for the sector.

Typing is a fancy motor exercise that has been linked to a person’s cognitive, psychological, and emotional state. Univariate evaluation of mechanical keyboard dynamics (in a small pattern) has not too long ago been proven to distinguish people with gentle cognitive impairment and Alzheimer’s illness from a standard management group. nQ Medical’s typing device is a novel technology that makes use of machine studying to seize and analyze a person’s typing efficiency on both a keyboard and/or a smartphone. Importantly, the nQ technology can seize knowledge constantly, non-invasively, and in an individual’s “pure” or on a regular basis surroundings, thus, making it a really promising screening device for early detection of Alzheimer’s illness.

About nQ Medical

nQ Medical, Inc. is a Digital Biomarker Discovery Platform of information modeling that may be tailored cross-disorder and readied for speedy scaling. nQ Medical’s AI-powered computational biomarker yields highly effective insights. We consider that the way in which our fingers work together with good telephones and computer systems can reveal the presence of sure neuromotor and neurocognition ailments like Parkinson’s, Alzheimer’s, ALS, and A number of Sclerosis. The potential of our know-how has been proven in medical analysis at MIT, backed by the Michael J. Fox Basis, the Cleveland Clinic and Massachusetts Basic Hospital. The advantageous management of typing and contact display kinematics, in addition to the frequent use of private gadgets like smartphones brings Actual World Knowledge to sufferers, caregivers, and clinicians. For extra data, please contact us: https://www.nq-medical.com/adpd/

Media Contact

R. A. Bavasso, Founder & CEO, nQ Medical, Inc., +1 860-373-3174, bavasso@nq-medical.com

Irma Rastegayeva, MSc, MSEM, FACHT, eViRa Well being, 339-927-0446, irmaraste@gmail.com

 

SOURCE nQ Medical, Inc.



Source link

Tags: ADPDAlzheimersBiomarkerClinicalConferenceDigitalDiscoveryDiseaseInternationallatestMedicalNewsPlatformResultsTrialUnveils
Advertisement Banner
Previous Post

Assisted living in Scotland will be powered by fibre connections

Next Post

$5.9 Billion Worldwide Alzheimer’s Disease Drugs Industry to 2027 – Impact of COVID-19 on the Market – ResearchAndMarkets.com

Delmar

Delmar

Next Post
$5.9 Billion Worldwide Alzheimer’s Disease Drugs Industry to 2027 – Impact of COVID-19 on the Market – ResearchAndMarkets.com

$5.9 Billion Worldwide Alzheimer's Disease Drugs Industry to 2027 - Impact of COVID-19 on the Market - ResearchAndMarkets.com

Discussion about this post

Recommended

O’Neill Center introduces program for those with or at risk for dementia

O’Neill Center introduces program for those with or at risk for dementia

2 years ago
New hope as research collaboration throws Alzheimer’s theory overboard

New hope as research collaboration throws Alzheimer’s theory overboard

2 years ago

Don't Miss

(2021-2026) Nursing Home Beds Market Size, Demand Status | Global Industry Segment Analysis, Growing Status of Key Players

Advice You Need To Know About Personal Development

May 12, 2021
Asceneuron Receives USD 2.2 Million Award from the Alzheimer’s Drug Discovery Foundation

Advocate Aurora Enterprises acquires national leader in home care and wellness offerings Senior Helpers

April 1, 2021
‘I’m in jail’: BPS mothers and caregivers voice concerns with district reopening plans

‘I’m in jail’: BPS mothers and caregivers voice concerns with district reopening plans

April 1, 2021
As Loved Ones Reunite After A Year, Dementia Experts Offer These Tips

As Loved Ones Reunite After A Year, Dementia Experts Offer These Tips

April 1, 2021

Categories

  • Alzheimer's
  • Assisted living
  • Caregivers
  • Dementia
  • Elder Care
  • Home Care
  • Mindfulness
  • Seniors advocate
  • Uncategorized
  • Wellness

Follow us

Recent News

(2021-2026) Nursing Home Beds Market Size, Demand Status | Global Industry Segment Analysis, Growing Status of Key Players

Advice You Need To Know About Personal Development

May 12, 2021
Asceneuron Receives USD 2.2 Million Award from the Alzheimer’s Drug Discovery Foundation

Advocate Aurora Enterprises acquires national leader in home care and wellness offerings Senior Helpers

April 1, 2021
March 2021
S M T W T F S
 123456
78910111213
14151617181920
21222324252627
28293031  
    Apr »
  • About Us
  • Contact Us
  • Privacy & Policy

© 2021 The Senior health Letter

No Result
View All Result
  • Home
  • Home Care
  • Elder Care
  • Wellness
  • Dementia
  • Caregivers
  • Alzheimer’s
  • Assisted living
  • Mindfulness
  • Seniors advocate

© 2021 The Senior health Letter